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PENGEKSPRESAN NEURAMINIDASE VIRUS SELESEMA BURUNG A 
(H5N1) SECARA HETEROLOGUS DALAM Kluyveromyces lactis DAN 
Escherichia coli 
ABSTRAK 
Pengekspresan neuraminidase (NA) virus H5N1 di dalam sistem 
pengekspresan mikrob yang ringkas dengan menggunakan Kluyveromyces lactis dan 
Escherichia coli sebagai perumah telah dikaji. Untuk penghasilan protein NA dalam 
K. lactis, dua jenis fragmen DNA NA terdiri daripada  1) jujukan penuh (1347 bp) 
dan 2) jujukan domain kepala (residu 63-449, 1161 bp) NA daripada 
A/Chicken/Malaysia/5858/2004 (H5N1) telah diamplikasi dan diklon ke dalam 
vektor pengekspresan pKLAC2 lalu menghasilkan konstruk plasmid yang dinamakan 
pKLAC2-NA and pKLAC2-NAHD. Kedua-dua plasmid kemudiannya diluruskan 
dan diintegrasikan ke bahagian promoter LAC4 di dalam genom K. lactis melalui 
rekombinasi homologus. Walaubagaimanapun, analisis protein yang dijalankan 
sebaik sahaja pengekspresan protein diinduksi tidak menunjukkan sebarang 
kehadiran protein rekombinan NA (rNA) terembes daripada mana-mana transforman 
yis. Oleh itu, jujukan penuh gen NA turut diamplikasi dan diklon ke dalam vektor 
pengekspresan pET-32 Xa/LIC dan seterusnya digunakan untuk mentransfomasikan 
E. coli Rosetta-gami 2(DE3). Analisis protein yang dijalankan selepas induksi 
pengekspresan protein menunjukkan bahawa protein rNA bersaiz ~ 62 kDa telah 
diekspres dalam bentuk jasad rangkuman (IBs). Seterusnya, untuk mendapatkan 
semula protein rNA yang bio-aktif, jasad rangkuman tersebut telah dipencil, dilarut 
dan dilipat semula menggunakan kaedah pencairan “pulsatile”. Pengaruh pH, suhu 
dan bahan kimia tambahan turut dikaji. Sekurang-kurangnya 27% protein terlarut 
berjaya dilipat semula, dan nilai aktiviti enzim yang  rendah telah direkodkan. 
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HETEROLOGOUS EXPRESSION OF AVIAN INFLUENZA A (H5N1) 
NEURAMINIDASE IN Kluyveromyces lactis AND Escherichia coli 
ABSTRACT 
The expression of H5N1 virus neuraminidase (NA) in simple microbial 
expression system utilizing Kluyveromyces lactis and Escherichia coli as the host 
was studied. For NA protein production in K. lactis, two types of NA DNA fragment 
composed of 1)  full length sequence (1347 bp) and 2) head domain sequence 
(residue 63-449, 1161 bp) from A/Chicken/Malaysia/5858/2004 (H5N1) were 
amplified and cloned into pKLAC2 expression vector generating plasmid constructs 
named pKLAC2-NA and pKLAC2-NAHD. Both plasmid were then linearized and 
integrated into the LAC4 promoter region of K. lactis genome through homologous 
recombination. However, protein analysis carried out upon the induction of protein 
expression did not exhibit the presence of secreted recombinant NA (rNA) protein by 
any of the yeast transformants. Hence,  the full length sequence of NA gene was also 
amplified and cloned into pET-32 Xa/LIC expression vector and subsequently used 
to transform E. coli Rosetta-gami 2(DE3). Protein analysis performed after the 
protein expression induction shows that ~ 62 kDa size rNA protein was expressed in 
the form of inclusion bodies (IBs). Next, to recover the bioactive rNA protein, the 
IBs were isolated, solubilized and refolded using pulsatile dilution method. The 
effects of pH, temperature, and chemicals additives were also investigated. At least 
27% of the solubilized IBs were successfully refolded, and low amount of enzyme 
activity was recorded. 
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CHAPTER 1  
1.0 Introduction 
For centuries, influenza virus specifically human influenza virus has 
become one of the most successful and threatening virus in human population 
(Adams, 2006). After three influenza pandemics occurred in 20
th
 century, H1N1 
‘swine flu’ arrived as the first influenza pandemic for 21st century (Trifonov et al., 
2009). Even though H1N1 virus had always been the major player in the event of 
influenza pandemics, another pandemic threat comes from highly pathogenic avian 
influenza (HPAI) A H5N1 virus. According to World Health Organization (WHO) 
(2015), ever since the first outbreak in 1997 and followed by 2004-2005 epidemic, 
this virus had constantly causing outbreaks around the globe. 
As the name implied, avian influenza A H5N1 mainly infected birds causing 
millions of loss in the poultry industries. However, cases of human infection had also 
been reported which mainly due to direct contact with the infected animals 
(Subbarao et al., 1998; Ku and Chan, 1999). A H5N1 is yet to obtain the ability to 
easily transmit within human population but recent finding which linked avian 
influenza virus with 1918 H1N1 virus (Taubenberger, 2006; Qi et al., 2012; 
Worobey et al., 2014) suggested that the possibility is definitely there. With possible 
cases of human to human infection reported (Wang et al., 2008; Hill et al., 2009) and 
the emergence of H7N9 recently, many fear that the event might be sooner than later 
(Horby et al., 2013). As the virus will continually circulate and mutate, no one can 
ever predict when the new reasserted H5N1 virus will emerge (Martin et al., 2006). 
Therefore, developing strategies and preparedness for the prevention of the influenza 
in the future are worthy steps to take. 
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Lesson from 2009 H1N1 pandemic showed that many aspect of the 
contingency plan need to be improved especially the availability and the accessibility 
of vaccines and antivirals (Morens and Taubenberger, 2012). Due to the 
unavailability of universal vaccine, influenza infection treatment had normally relied 
on the antiviral such as M2 ion channel inhibitors (adamantanes) and neuraminidase 
(NA) inhibitor (oseltamivir, zanamivir and peramivir) [Food and Drug 
Administration (FDA), 2015]. However, with the ability of influenza viruses to 
continually mutate, having a long lasting drug is nearly impossible. Adamantanes for 
example are no longer recommended as at least half of the influenza A subtypes had 
gained resistance toward the drug [Centers for Disease Control and Prevention 
(CDC), 2015; Dong et al., 2015). To date, only NA inhibitor remains effective albeit 
the emergence of a few resistance cases reported towards oseltamivir and zanamivir 
(Samson et al., 2013). 
NA inhibitors were designed to block the activity of NA protein of influenza 
virus which is important for the released of new viral progeny, thus preventing the 
spread of the viruses in the host body (Shtyrya et al., 2009). When the crystal 
structure of A (H5N1) NA was discovered and solved in 2006, it was revealed that 
group-1 NA (N1, N4, N5 and N8) and group-2 NA (N2, N3, N6, N7 and N9) are 
structurally different. In group-1 NA, a cavity was found adjacent to the active site 
close to ligand binding hence suggesting possibilities to develop new drug by 
exploiting this particular region (Russell et al., 2006). 
Drug discovery however is a very demanding process where large amount 
of the protein in pure and active form is required. Due to low number of NA protein 
on the virus, obtaining the desired amount could be the limiting factor for this 
process. Most method currently used to produce the protein in large scale are costly 
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and laborious, and may also restricted to limited number of laboratories equipped 
with at least biosafety level three (BSL-3) facilities (Yongkiettrakul et al., 2009). 
Therefore, in this study two types of microbial host, Kluyveromyces lactis (yeast) and 
Escherichia coli (bacteria) were utilized to express the influenza A (H5N1) NA. 
1.1 Objectives 
The main objective of this study is to produce influenza A (H5N1) NA 
using K. lactis and E. coli as hosts. The following steps are employed:  
1) Transformation and expression of avian influenza A (H5N1) NA in K. lactis. 
2) Optimization of avian influenza A (H5N1) NA expression in E. coli. 
3) Screening of refolding condition to recover bioactive recombinant NA produced in 
E. coli. 
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CHAPTER 2 
2.0 Literature Review 
2.1 Influenza: epidemiology and virology 
Listed alongside Ebola, Hantavirus, and Marburg virus as one of the most 
deadly virus, influenza earned its reputation by claiming millions of human life 
throughout the history (Schwar, 2014). The oldest record of influenza was probably 
written by Hippocrates in 412 BC who was reporting a major epidemic called 
“Cough of Perinthus” in the seventh chapter of the sixth book of Epidemic as a part 
of an ancient Greek medical collection known as Corpus Hippocraticum (Adams, 
2006; Pappas et al., 2008; Wohlbold and Krammer, 2014). The name influenza 
however is not that ancient. The word “influenza” appeared for the first time in 1357 
AD originating from an Italian word meaning influence. The first influenza 
pandemic was recorded in 1580 that began in Europe and later found its way to Asia 
and Africa (Adams, 2006).  
Following the timeline, series of influenza epidemic and pandemic had 
occurred but none could be compared to the 1918-1919 influenza pandemic so called 
“Spanish Flu” caused by H1N1 virus killing ~ 50 million people or perhaps more 
(Patterson and Pyle, 1991; Johnson and Mueller, 2002; Crosby, 2003). Other than the 
unusual mortality rate, many aspect of the pandemic such as the origin of the strain, 
the vulnerability of young adults (20-40 years old) towards the infection, and the 
characteristics of three distinct influenza epidemic waves remain obscure (Shanks 
and Brundage, 2012; Morens and Taubenberger, 2012; Worobey et al., 2014). Later, 
20
th
 century witnessed another pandemics; Asian Flu (H2N2, 1957-1958) and Hong 
Kong Flu (H3N2, 1968-1969 ) resulting 1 to 4 million of death (van Riel et al., 2010; 
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Ligon, 2005). Studies showed that the latter pandemic was indeed related to the 
1918-1919 influenza (Taubenberger and Morens, 2006).  
Due to its glorious history, the arrival of the first 21
st
 century influenza 
pandemic the 2009 H1N1 was not a surprise. Commonly known as “Swine Flu”, the 
new strain appeared to be a combination of a previous triple re-assortment of bird, 
swine and human flu viruses with a Eurasian pig flu virus (Trifonov et al., 2009; 
Dawood et al., 2012). Albeit years of efforts and preparedness, more than 200 000 
people were estimated to lost their lives globally and in the United State alone, the 
death penalty was in the range of 8000 to 18 000 lives (Shrestha et al., 2011; 
Dawood et al., 2012).  This number might be statistically low compared to the older 
pandemics but the 2009 H1N1 virus showed two outstanding and worrisome 
features; able to cause major out-of-season epidemics in temperate countries and 
severely infected the young and healthy people which had been seen in the 1918-
1919 influenza pandemic hence raising the anxiety for the emergence of more 
notorious influenza strain in the future (Shindo and Briand, 2012).  
2.1.1 Viral type and structure 
There are three types of influenza virus; influenza A, B and C representing 
three of the five genera of Orthomyxoviridae family (Palese and Shaw, 2007). Even 
though all of the three types infected humans, influenza B and C almost exclusively 
replicated in human while influenza A has the widest range of host including non-
human such as poultry, pigs, sea mammals, horses and bats (Hay et al., 2001; 
Taubenberger and Morens, 2010; Wohlbold and Krammer, 2014). These viruses 
normally evolved through antigenic drift (mutation within the virus) or antigenic 
shift (reassortment of two or more strains). While influenza B continually undergoes 
antigenic drift causing severe epidemics, influenza A with its capability to evolve 
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both ways caused greater impact in terms of annual epidemics and pandemics (Hay 
et al., 2001). 
Based on its diverse genetics, influenza A virus subtypes are further 
classified based on the sequence and the antigenicity divergence of the virus’ surface 
glycoprotein, haemaglutinin (HA) and neuraminidase (NA) (Palese and Shaw, 2007). 
Currently there are 18 HA subtypes (H1-18) and 11 NA subtypes (N1-N11) had been 
identified in which only a certain type of HAs (H1, H2 and H3) and NAs (N1 and 
N2) were found to circulated among humans. For human cases associated with 
poultry outbreaks, H5, H6, H7, H9, H10, N3, N7, N8, and N9 are the usual suspects 
(Wohlbold and Krammer, 2014).  
The structure and organization of all influenza are generally similar but 
influenza A and B are more alike compared to influenza C. The virus particle of 
influenza A and B are commonly in spherical shape with ~ 100 nm in diameter but 
can also exceed 300 nm in length when in filamentous shape, whereas for influenza 
C, the viruses can exist in a long cordlike structure with ~ 500 µm in size on the 
infected cell surface (Bouvier and Palese, 2008). These enveloped viruses also share 
the same genetic material which is negative sense single-stranded RNA albeit 
different in number, seven pieces for influenza C and eight for influenza A and B. In 
total the genome size of influenza A and B is ~ 13, 600 and ~ 14, 600 bp respectively 
and as influenza C has one less RNA segment the size is smaller ~ 10, 000 bp 
(Klenk, 2007; Swiss Institute of Bioinformatics, 2010). Through mRNA splicing, the 
eight pieces of influenza A and B vRNA encode ten or eleven proteins needed for the 
survival of the virus. These proteins are 1) basic polymerase subunit; PB1 and PB2 
(some strain of influenza A produce an accessory protein PB1-F2), 2) acidic 
polymerase subunit PA, 3) surface glycoprotein; HA and neuraminidase NA, 4) 
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nucleoprotein NP (RNA binding protein), 5) matrix protein; M1, M2 for influenza A, 
and NB and BM2 for influenza B, and 6) the interferon antagonist protein; non-
structural protein 1 (NS1) and nuclear export protein (NEP/NS2). The main 
difference between influenza C and influenza A and B genomic composition is that, 
there is only one glycoprotein present on influenza C viral surface which is 
haemagglutinin-esterase-fusion (HEF) protein replacing the HA and NA proteins on 
the surface of influenza A and B (Bouvier and Palese, 2008). 
As shown in Figure 2.1, despite the variations of the envelope composition, 
the virion organization of all influenza is quite alike (Bouvier and Palese, 2008). The 
viral core contains NEP protein and helical viral ribonucleoprotein complexes 
(vRNPs) composed of NP coated RNA segments and heterotrimeric RNA-dependent 
RNA polymerase (consist of PB1, PB2 and PA) (Nayak et al., 2009). Surrounding 
the core is the lipid-containing viral envelope made by M1 protein and the variations 
of envelope proteins (Influenza A: M2, HA, and NA; influenza B: BM2, NB, HA 
and NA; influenza C: CM2 and HEF) (Klenk, 2007; Bouvier and Palese, 2008).  
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Figure 2.1: Different structure of influenza A, B and C. Adapted from Swiss 
Institute of Bioinformatics (2010). 
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2.1.2 Virus replication cycle 
The life cycle of influenza virus was basically a rotation of four stages; 1) 
host cell invasion; 2) nucleus take over and host cell resources’ exploitation (vRNPs 
enter the nucleus, transcript and replicate its own genome); 3) departing of the 
vRNPs from the nucleus; and 4) final assembly and budding at the host cell plasma 
membrane getting ready for the next cell invasion (Samji, 2009). The first stage 
began with attachment process involving HA, the most abundant surface 
glycoproteins. Approximately 80% of the influenza virus surface glycoproteins are 
made of HA. Crystal structure of HA solved by Wilson et al., (1981) showed that 
this molecule is a trimer comprised of two distinct regions; a triple-stranded coiled-
coil of α-helics as a stem extended from the membrane and antiparallel β-sheet at the 
top of the stem as the globular head where N-acetylneuraminic (sialic) acid (SA) 
receptor binding site is located. For H1 subtype HA, surrounding the receptor 
binding site are five predicted antigenic sites. The homotrimer will bind to SA found 
on the host cell’s membrane surface (Skehel and Wiley, 2000). Influenza HA 
preferentially binds to two types of galactose-linked sialic acid; SA α2,6-Gal for 
human viruses and SA α2,3-Gal for avian virus. In human, SA α2,6-Gal is 
dominantly expressed on the upper respiratory tract while the lower part expressed 
both types of SA. This phenomenon explained why H5N1 infection tends to cause 
pneumonia and the main reason for human to be more susceptible to H1N1 virus 
compare to H5N1 virus (Skehel and Wiley, 2000; Voet and Voet, 2004). 
Following the attachment, the virus was endocytosed allowing the virus to 
enter the host cell in the form of endosome. The low pH of the endosome of around 
five to six will trigger the conformational change of HA exposing the fusion peptide 
that mediates the viral and endosomal membranes fusion hence internalizing the 
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vRNPs into the cytoplasm (Sieczkarski and Whittaker, 2005; Stegmann, 2000). 
vRNPs were then directed into the host cell nucleus though viral proteins nuclear 
localization signals (NLSs) for the synthesis of both viral RNA, the capped and 
polyadenylated messenger RNA (mRNA) to be used as the template for viral protein 
translation and vRNA segments to form the genomes of progeny virus (Boulo et al., 
2007; Bouvier and Palese, 2008).  
By hijacking the host’s transcription machinery the viral mRNA was 
synthesized using a process called “cap snatching” process, and once polyadenylated 
and capped, the viral mRNA will be transported out of the nucleus and translated. As 
for the negative sense vRNPs, the RNA complex appeared to be exported from the 
nucleus by the viral proteins M1 and NEP/NS2 (Cros and Palese, 2003). The three 
envelope proteins, HA, NA and M2 synthesized on the membrane-bound ribosomes 
will undergo post-translational modification prior to the viral assembly. Then the 
vRNA was encased in the capsid protein, and together with new matrix protein, the 
protein complex was transported to sites at the cell surface where envelope HA and 
NA components have been incorporated into the cell membrane. Progeny virions 
were formed and released by budding which probably initiated by an accumulation 
of M1 matrix protein at the cytoplasmic side of the lipid bilayer. The progeny virions 
were released from the host cell surface by cleaving of the terminal sialic acid 
residues by NA protein (Bouvier and Palese, 2008). 
2.2 Avian influenza A H5N1 
Among influenza A virus, other than H1N1 virus, another influenza threat 
came from avian influenza virus particularly a highly pathogenic avian influenza 
(HPAI) A H5N1 virus. First identified in Italy in the early 1900s, H5N1 was known 
as “avian flu” or “bird flu”. This virus had caused a large scale of death in poultry 
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worldwide ever since, yet it was very rare to find the infection of H5N1 in human. At 
least, not until the first report of chicken-to-human transmission case in 1997 in 
Hong Kong (Subbarao et al., 1998; Ku and Chan, 1999). Following the first outbreak 
and the 2004-2005 epidemics, H5N1 had continually caused outbreaks around the 
globe and occasionally accompanied by transmission to human with 50% fatality rate 
(Neumann et al., 2010). Despite predominantly targeting animals, the possibility for 
human to be the main target is undeniable as the notion was supported by the 
possible case of human-to-human transmission (Wang et al., 2008; Hill et al., 2009) 
and findings that linked the avian influenza virus with the notorious 1918 H1N1 
virus (Taubenberger, 2006; Qi et al., 2012; Worobey et al., 2014).  
2.2.1 The evolution of human avian influenza A (H5N1) 
For decades avian influenza had only infected bird causing outbreaks mostly 
in Europe and America (Adams, 2006; Petsko, 2005). However, in 1996 when an 
HPAI H5N1 virus was isolated from geese following the virus outbreak in 
Guangdong Province in China, the virus demography was no longer the same. It was 
proven that this virus is the HA donor for the latter reassortant H5N1 virus in the 
1997 Hong Kong outbreak (de Jong and Hien, 2006). Though the spreading of the 
virus was managed to be controlled by killing millions of chicken and the number of 
infection was relatively low, the death rate deserved an attention as 33% of the 
infected human died (6 out of 18) (Chan, 2002). 
By the end of 2003 and in the early 2004, as H5N1 virus strain started 
making its way out of China, outbreaks began to occur in a few other countries, 
mostly South East Asia (Petsko, 2005). The 2004 strains which evolved from 1999-
2002 were also known as Z genotype or “Asian lineage HPAI A (H5N1), and can 
further be divided into two antigenic clades; clade 1 and clade 2. Human and bird 
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isolates from Thailand, Vietnam and Cambodia, and bird isolates from Malaysia and 
Laos belongs to clade 1 (Webster and Govorkova, 2006; Pal, 2014). In February of 
the same year, the virus was found to have gained the ability to infect non-human 
mammals when the strain was detected in pigs in Vietnam (Petsko, 2005; Choi et al., 
2005). The second clades which responsible for 2005 -2006 human infection were 
first identified from China, Indonesia, Japan and South Korea birds’ isolate (Pal, 
2014). The viral strain continued to spread outside Asia when it hits Turkey and Iraq 
in Jan 2006 followed by other Middle East countries such as Azerbaijan and 
Northern Africa. From 2007 onward most of human case infection was reported 
mainly in Indonesia and Egypt. To date over 800 cases were reported worldwide 
(from 2003) with near 60% of fatality (WHO, 2015).  
2.2.2 A H5N1 in Malaysia 
The first outbreak of HPAI A (H5N1) subtype in Malaysia was reported in 
August 2004 in a village in the state of Kelantan (Alexander, 2007). The virus was 
transmitted from smuggled fighting cocks from neighbouring country to the local 
village chickens, and weeks after, eight more outbreaks were reported. No human 
infection or death was reported and the disease was brought under control by 
depopulation, poultry and birds quarantine/clinical surveillance and movement 
restriction of birds and their products (Tee et al., 2009).  
However, in February 2007 another outbreak of HPAI A (H5N1) occurred 
in Malaysia in other regions over wider areas including several villages in Kuala 
Lumpur, and along the industrial area of western coast of Peninsular Malaysia in the 
state of Perak and Pulau Pinang. If 2004 HPAI A (H5N1) strain was revealed to be 
highly similar to strains isolated from Vietnam and Thailand, the 2006 strains 
phylogenetic analysis showed that the latter strain was closer to the isolates from 
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China and Indonesia. The disease was again brought down by control and 
preventative efforts, yet another outbreak re-occurred in another village in the state 
of Selangor in June 2007 and finally resolved several month later (Tee et al., 2009).       
2.2.3 The pandemic potential 
Ever since the outbreak in 1997, H5N1 virus had continually undergone 
various adaptations and multiple genetic re-assortments and became more virulence 
with wider host range and location (Le and Nguyen, 2014). Irrefutably, a new strain 
of HPAI A H5N1 virus is expected and for HPAI A H5N1 virus to be the main 
character in the next pandemic, all it has to obtain is the ability to easily transmit in 
human population unnoticed or hardly recognized by human immunity system and 
causing severe disease (Moscona, 2005). To do that, a very efficient attachment and 
replication system is needed and HA protein plays a very important role as it is on 
the front line of the virus invasion process by recognizing the cell glycan receptor for 
attachment. The human receptors, SA α2,6-Gal (SA α2,3-Gal expressed by avian 
host) is the first obstacle and with a few changes of amino acid in the receptor-
binding pocket of the H5N1 HA protein there is possibility for the changes of 
receptor specificity (Naeve et al., 1984). For replication process, PB2 protein is one 
of the main components for RNA replication. Glu-to-Lys mutation at location 627 of 
PB2 was found related to the adaptability of the virus in mammal (Gambotto et al., 
2008). Evidently these idea might actually work as some scientists had 
experimentally proven that with certain mutations this virus can evolve to a very 
threatening strain and even capable of transmitting through air which is very 
alarming (Herfst et al., 2012; Imai et al., 2012; Wilker et al., 2013). 
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Though we are lucky that the virus has yet to obtain the ability to be easily 
transmitted among humans, the possibility of the event might be closer as 2013 
witnessed the most recent influenza outbreak in China caused by a novel avian 
influenza A H7N9 virus which infected more than 100 of people in that year alone 
with 20% - 30% of fatality rate (Horby et al., 2013). So far, the virus has been 
hypothesized to be evolved at least from four origins (Liu et al., 2013). Quoted as 
“…unusually dangerous virus to humans.”, H7N9 showed unusual prevalence of 
older males, easily transmitted to human from poultry (in comparison with H5N1) 
and harder to spotted as it didn’t kill the poultry thus allowing it to spread silently 
hence wrecking the nerves among researchers (Shadbolt, 2013; Arima et al., 2013; 
Devitt, 2013).  
2.2.4 Pathogenesis of avian influenza A (H5N1) in human  
Once being infected by the influenza virus, after two or more days of 
exposure the person will normally experience an influenza-like illness such as fever, 
cough, shortness of breath, sore throat, muscle aches, diarrhea, and conjunctivitis 
(CDC, 2008; Gambotto et al., 2008)  And if not well treated, it may progress to 
pneumonia and in worse scenario, may lead to acute respiratory distress syndrome 
(ARDS), multi-organ failure and eventually death (Maines et al., 2011; Thanh et al., 
2008).  
The alveolar epithelial cells has always been the main target for influenza A 
replication, which is why diffused alveolar damage (DAD) and haemorrhage in the 
lung were often observed on the infected patients (Uiprasertkul et al., 2007; 
Korteweg and Gu, 2008; Chan et al., 2013). However, compared to seasonal 
influenza infection and 2009 H1N1 which mostly affected the upper respiratory tract, 
H5N1 preferred the lower region and in some rare and severe cases the virus spread 
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beyond the lung by infecting trachea, brain, intestine, lymphoid tissues and even 
penetrate the placental barrier (Uiprasertkul et al., 2005; Gu et al., 2007; Korteweg 
and Gu, 2008; Gao et al., 2010; van den Brand et al., 2014).   
The cell and organ damage due to H5N1 infection were thought to be 
associated with viral replication through either cytolytic (degeneration of cells) or 
apoptotic (programmed cell death) mechanisms (Korteweg and Gu, 2008; Alberts et 
al., 2002; van den Brand et al., 2014). This theory though not fully proven was 
supported by the evidences of active viral replication in many part of the respiratory 
tract isolated from the infected humans, in mammalian model such as ferret and 
mice, and also in in vitro models of human respiratory epithelial cells (Korteweg and 
Gu, 2008; Chan et al., 2013; Belser and Tumpey, 2013). 
Other than viral replication, extensive studies on the role of dysregulation of 
cytokines (cells signalling molecules which covered a wide range of peptide, 
glucopeptides, and protein responsible for mediating the immune system) deduced 
that it could be one of the key mechanisms involved in the pathogenesis of H5N1 
influenza (Yu et al., 2011; Hui et al., 2009; Mandal, 2013). Besides that, even though 
the exact roles remains unclear, it was believed that other factor such as up-
regulation of tumor necrosis factor-related apoptasis-inducing ligand (TRAIL) and 
reduced cytotoxicity of CD8
+
 lymphocytes are also taking part in the pathogenesis of 
this virus (Zhou et al., 2006; Hsieh and Chang, 2006). 
2.2.5 Prevention and treatment 
Following the outbreak of influenza A H5N1 in 2003 which triggered the 
surge for pandemic preparedness, WHO issued a checklist to guide the development 
of national inﬂuenza pandemic preparedness plans in 2005 (Berera and Zambon, 
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2013). The list basically addressed the need to develop a good communication plan 
in handling the pandemic, surveillance system to monitor the antivirals usage and or 
sale, health and research facilities, and increasing the awareness among the 
population regarding the pandemics and actions to take when it strike (WHO, 2005). 
In 2007, WHO also outlined another guideline to help national authorities to stop the 
development of the pandemic when it first detected (Berera and Zambon, 2013). 
Based on early mathematical modelling studies, rapid containment strategies and 
protocols were laid out (WHO, 2007).  
Therefore, when the imminent threat of A (H1N1) pdm2009 was issued by 
WHO in April 24, 2009, the years of plans and strategies were rapidly implemented 
across the globe. Even though the plans manage to lower the number of death in 
2009 pandemic as compared to the previous one, many insisted that we can and 
should do better in the future and if there is one thing we can learn from this genius 
virus it is that survival requires non-stop progression, and so must we. As we learned 
from the pandemic post mortem, the availability of the treatment is useless if it 
cannot be delivered on time (Fedson, 2013). Therefore, the revision of every aspects 
of the plans such as better trained clinician, additional experienced technicians, more 
superior surveillance system and even better vaccines and antivirals in terms of 
effectiveness, accessibility and rapid production are required (Fineberg, 2014; Berera 
and Zambon, 2013). 
In the fight against influenza pandemic, many believe that the ultimate way 
to win the war is by equipping ourselves with the ultimate vaccine and or the 
capacity to produce the vaccines rapidly (Fedson, 2013). However the continual 
mutation of the virus makes the idea almost impossible to materialize and despite the 
promising potential shown by several developing “pre-pandemic vaccines” the 
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question remains whether it will actually work against the actual pandemic virus as 
no can ever know for certain which virus will be responsible (Osterhaus, 2007).  
Nevertheless, by June 2008 at least three H5N1 vaccines for human were licensed; 
Panvax by CSL Limited approved by Australia (June 2008), Prepandrix produced by 
GlaxoSmithKline approved by European Union (May 2008), and Sanofi Pasteur's 
vaccine approved by United States in April 2007 (Roos, 2008). In 2013 despite 
containing the controversial oil-in-water emulsion adjuvant AS03, FDA approved 
GlaxoSmithKline’s vaccine Q-Pan to be included in the US pandemic emergency 
vaccine stockpile (La Vigne, 2013). 
In the 2009 pandemic, as the vaccines for pdm2009 H1N1 were only 
approved by FDA by September 15 2009, antivirals were the first defence against the 
pandemic where they were stockpiled by most of countries (Berera and Zambon, 
2013). Influenza treatment has always highly relied on antiviral drugs which mostly 
designed by targeting viral proteins essential for the virus replication cycle. Among 
the designed drugs are viral attachment and fusion inhibitor, M2 blockers, viral 
RNA-dependent RNA polymerase (vRdRP) inhibitors (to interrupt transcription and 
viral genome replication process), NP inhibitor, and NA inhibitor (de Clercq, 2006; 
Loregian et al., 2014).  
Historically, adamantane derivatives, amantadine and rimantadine were the 
first two drugs available for influenza treatment designed specifically active against 
influenza A virus. These M2 ion channel blockers function by interrupting the viral 
uncoating process (de Clercq and Neyts, 2007). However, they only worked on 
influenza A virus due to the exclusive presence of M2 ion channel on this virus type, 
and were always associated with rapid emergence of drug-resistance viral strain (von 
Itzstein, 2007; Bright et al., 2005; He et al., 2008). Up to 2013, nearly half of the 
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influenza A viruses had conferred the resistance toward adamantanes with H1, H3, 
H5, H7 H9, and H17 subtype bearing the high-level resistance, hence restricting the 
usage of the antiviral (Dong et al., 2015; CDC, 2015) 
As of for today, only NA inhibitors (oseltamivir, zanamivir, and peramivir) 
were proven affective, licenced, and primarily recommended against the circulating 
influenza viruses (CDC, 2015). These antivirals however were not without limitation. 
Oseltamivir for example was not to be used by high-risk patients (patients less than 
one year or diagnosed with liver or renal failure) and the uptake has to be within 24-
48 hours after the onset of infection. Zanamivir and peramivir were only approved 
for patient older than five and 18 years old respectively (FDA, 2015). And most 
recently, a polymerase inhibitor was approved known as favipiravir but only in Japan 
with a very strict usage (Ison, 2015). 
2.3 Neuraminidase: the drug target 
The envelope of influenza A virus is generally composed of a lipid bilayer 
and integral membrane proteins including the two major glycoproteins, HA and NA 
protruding from the membrane covering the surface of the virus like spikes (Colman, 
1994; Goodsell, 2009; Reddy et al., 2015). The nomenclature of the influenza A 
strains are based on these two glycoproteins which are also the key determinant of 
the virus virulence and pathogenesis (Korteweg and Gu, 2008; Zhou et al., 2009; 
Gamblin and Skehel, 2010). HA plays the starring role by recognizing and binding to 
the sialic acid existed on the host cell during the attachment process and the 
subsequent membrane fusion. NA major role on the other hand is to cleave the α-
ketosidic linkage between the sialic acid and an adjacent sugar residue that anchoring 
the newly assembled virion on the host cell surface so that it will not get stuck 
(Wagner et al., 2002; Goodsell, 2009; Shtyrya et al., 2009). 
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For decades, both HA and NA had received significant amount of attention 
as drug target, but only a few of NA inhibitors were proven to be affective as a 
broad-spectrum inhibitor while most of the candidates were either strains dependent, 
cytotoxic, or resistance prone (Eyer and Hruska, 2013; Edinger et al., 2014). Despite 
the lack of successful antiviral or vaccine, given the continuous threat, future efforts 
should not be deter but continued and progress should be made to further understand 
the virus and improve the technology (Littler and Oberg, 2005; Atkins et al., 2012; 
Saha et al., 2013). 
2.3.1 Neuraminidase structure  
Influenza NA was first discovered by George Hirst and soon after became 
the target of influenza therapeutics approach. But the limited technology at that time 
was not able to fully unfold the protein structure (Hirst, 1942; Wohlbold and 
Krammer, 2014). Admittedly, it took nearly 40 years for the first NA to be purified 
and crystallized, and the N2 NA was found to be an association of four identical 
monomers where each monomer was made of six four-stranded antiparallel β-sheets 
arranged in the formation propeller blade (Varghese et al., 1983) as illustrated in 
Figure 2.2A. Each of the nascent polypeptide consists of four parts; N-terminal 
cytoplasmic domain, transmembrane domain, stalk region and the globular head 
domain where the catalytic site is located (refer Figure 2.2B) (Air, 2012; Chen et al., 
2012). The total size of NA protein is around 450-480 amino acids depends on the 
NA types, portraying the low sequence similarity yet they do have a stable topologies 
and a conserved nine amino acids sequence “ILRTQESEC” as part of the enzymatic 
active site (Chen et al., 2012; Doyle et al., 2013). 
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Figure 2.2: Structure of influenza A virus NA.  
(A) 3D crystal structure of 1918 influenza A H1N1 NA globular head domain shown 
as tetramer displaying conserved 6-bladed propeller structure coloured in green with 
one of the subunits coloured differently from blue to red along the N to C chain 
terminus for each blade. Each blade is made up of four anti-parallel beta sheets 
stabilized by disulphide bonds and connected by loops of varying length. Picture was 
adapted from Royuela (2013). 
(B) Schematic diagram of NA protein showing cytoplasmic, transmembrane, stalk 
region and globular head domains, and universally conserved ILRTQESEC sequence 
(arrow pointed) adapted from Wohlbold et al., (2014). 
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For avian influenza A (H5N1) NA specifically, the crystal structure  was 
solved in 2006 showing that NA of influenza A are phylogenetically divided into two 
distinct groups, group-1 containing N1, N4, N5 and N8 subtypes, and group-2 
contain the rest of NA subtypes (N2, N3, N5, N7 and N9). Superposition of the 
active site of three group-1 NA, (N1, N4 and N8) produced a higly similar active site 
region whereas superposition of the active of N1 (group-1) and N9 (group-2) in 
contrast showed a markedly difference in the 150-loop region (Russell et al., 2006). 
The latest isolated NA (N10 and N11) however, showed little resemblance to any 
group (Wohlbold and Krammer, 2014). 
2.3.2 Neuraminidase inhibitor 
The SA binding site of NA is comprised of the following amino acids, 
Arg118, Asp151, Arg152, Arg224, Glu276, Arg292, Arg371 and Tyr406 which are 
conserved among influenza A and most NA inhibitors were designed to interrupt the 
binding by mimicking the SA composition (Mitrasinovic, 2010). The analogue of 
SA, 2-deoxy-2,3-didehydro-N-acetylneuraminic acid (DANA) (Figure 2.3A) was 
developed in 1960s as inhibitor for many bacterial and viral NA (Meindl and Tuppy, 
1969). With the successful configuration of NA structure in 1983, the first effective 
NA inhibitor known as zanamivir (Figure 2.3B) which is a derivative of DANA was 
discovered, and marketed under the trade name Relenza (von Itzstein et al., 1993; 
Wohlbold and Krammer, 2014). Another NA inhibitor, oseltamivir (Figure 2.3C; 
marketed as Tamiflu) was also designed based on the same structure but with a 
different approach and received more attention due to its ease of administration and 
systemic availability as it was designed as capsule compared to the inhalant Relenza 
(de Clercq and Neyts, 2007; Air, 2012). 
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Figure 2.3: Chemical structure of the NA inhibitors. Adapted from McKimm-
Breshkin (2012). 
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One of the reasons why the search for new inhibitor was never stopped is 
that from time to time the influenza virus will most definitely become resistance 
towards the current inhibitor as shown by the worldwide spread of oseltamivir-
resistant seasonal A (H1N1) during the 2007-2009 influenza seasons. Clinical and in 
vitro reduced susceptibility mostly towards oseltamivir had been reported for H5N1 
and H3N2. And most of the resistance strains carried NA substitution mutations such 
as H274Y, N294S, E119G and I122R (Samson et al., 2013). Therefore, along with 
advances in technology particularly in drug discovery such rational drug design and 
X-ray crystallography, dozens of new or modified NA inhibitors had been suggested 
and tested (Eyer and Hruska, 2013).  
One NA inhibitor candidate developed by structure-based design is an 
injectable drug known as peramivir (Figure 2.3D) developed by Biocryst. A 
cyclopentane derivative was finally approved and commercially marketed as 
Rapibav. Because it is injectable, peramivir is very applicable for patient who cannot 
be treated by pills or with limited lung capacity (Kohno et al., 2011; FDA, 2015). 
Another promising candidate is laninamivir (code name, R-125489) (Figure 2.3E), 
another SA analogue that demonstrated a long-acting inhibitory activity and was 
approved for usage by Japan (Kubo et al., 2010; Samson et al., 2013). Groups of 
researcher had also studied the possibility to develop the inhibitor by using the 
natural compound. This approach was still under development and with numbers of 
possible compounds, many trial and error are on the way (Shan et al., 2012; Ikram et 
al., 2015). 
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2.3.3 Neuraminidase production 
When the NA was discovered and set as the drug target, the urgency to 
extract the active protein to study the protein began (Wohlbold and Krammer, 2014). 
Conventionally, NA was prepared by proteolytic cleavage or detergent-treatment of 
the viral envelop followed by subsequent purifications to obtain the catalytic head 
domain. Two proteases commonly used for the extraction procedure are pronase and 
bromelain (Seto et al., 1966; Aitken and Hannoun, 1980; Cabezas et al., 1982; 
McKimm-Breschkin et al., 1991; Franca de Barros et al., 2003). Pronase refers to a 
protease cocktail (contain at least ten proteolytic components) secreted by the 
bacteria Streptomyces griseus and bromelain is another protease mixture produced by 
pineapple mostly from fruit and stem parts (Sweeney and Walker, 1993; Kelly, 
1996). As both of the proteins have a broad range of protein specificity, this method 
tends to complicate the downstream purification of NA due to cleavage of other 
protein such as HA. Therefore, a new approach to increase the protein specificity was 
applied by genetically engineered a thrombin cleavage site at the stalk region of NA 
(Wanitchang et al., 2010). 
As the demand for the protein will never cease to stop mainly for the 
inhibitor screening purposes, new and perhaps simpler production methods were 
indeed needed. As an alternative, the production of NA protein by using recombinant 
technology had been considered and implemented. Various type of protein 
expression system had been explored such as insect cells with baculovirus expression 
system (Johansson et al., 1995; Schmidt et al., 2011; Margine et al., 2013), CHO-K1 
cells (Tanimoto et al., 2004), human embryonic kidney cells (Nivitchanyong et al., 
2011), and the yeast such as Pichia pastoris (Yongkiettrakul et al., 2009)and 
Kluyveromycis lactis (Tsai et al., 2011) . 
